Genmab — April 2021

[Bulder]

Asco abstract titles i eftermiddag. 10.00 am ET må være kl. 15 da ti.

[Bulder]

Jeg opgiver. Hver eneste søgning giver resultater fra 2019 eller 2020. Håber andre har bedre held.

[deleted-user]

Bulder - er det ikke 16.00?

[GeorgeBest]

Jeps, ET er 6 timer efter CET. Du får snart en ny chance Bulder;-)

[Bulder]

fåk, jeg er forud for min tid

[E_L]

something is out, but site keeps crashing lol, only 1 I found so far;

[E_L]

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. -abstract 9006

[GeorgeBest]

As always E L find the news BEFORE they are published;-)

[E_L]

you are really telling me in kind words that I should get a life, right ?

[Bulder]

Where do you find it. I've found lots of interesting things, but all from 2020

[GeorgeBest]

No not at all, very happy with the service you provide to Genmab investors here on PI D-)

[GeorgeBest]

[Rondo]

Keep Going [email protected]....!!!

[Bulder]

Look at the share. It's E L again

[E_L]

just had another link, but maybe this is best,
via https://meetinglibrary.asco.org/results/amivantamab;page=0?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D , ticked the year for 2021

[E_L]

2 for epcoritamab - Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity. and - Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

[Bulder]

It seems there are 2 epco abs https://meetinglibrary.asco.org/results/epcoritamab?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D&page=1

[E_L]

i think those 2 will be the 2 most important ones?

[E_L]

or could be, depends on data offcourse

[E_L]

Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.